Hims & Hers Health Inc. reports Q3 revenue up 49% year over year-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

Hims & Hers Health Inc. reports Q3 revenue up 49% year over year

Reuters2025-11-04

Hims & Hers Health Inc. reports Q3 revenue up 49% year over year

Hims & Hers Health Inc. reported third quarter 2025 revenue growth of 49% year over year. Adjusted EBITDA increased by 53% year over year. Free cash flow for the third quarter was $79.4 million, unchanged from the same period in 2024. For the fourth quarter of 2025, the company expects revenue between $605 million and $625 million, and Adjusted EBITDA of $55 million to $65 million, with a projected Adjusted EBITDA margin of 9% to 10%. Full year 2025 revenue is expected to be between $2.3 billion and $2.4 billion. The company is in ongoing discussions with Novo Nordisk to potentially offer Wegovy injections and oral Wegovy, pending FDA approval, through its platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hims & Hers Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251103753411) on November 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

empty

No comments yet

Most Discussed

7x24

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2580540228?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 05:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580540228","market":"nz","top_or_hot":-1,"title":"Hims & Hers Health Inc. reports Q3 revenue up 49% year over year","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hims &amp; Hers Health Inc. reports Q3 revenue up 49% year over year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hims &amp; Hers Health Inc. reported third quarter 2025 revenue growth of 49% year over year. Adjusted EBITDA increased by 53% year over year. Free cash flow for the third quarter was $79.4 million, unchanged from the same period in 2024. For the fourth quarter of 2025, the company expects revenue between $605 million and $625 million, and Adjusted EBITDA of $55 million to $65 million, with a projected Adjusted EBITDA margin of 9% to 10%. Full year 2025 revenue is expected to be between $2.3 billion and $2.4 billion. The company is in ongoing discussions with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> to potentially offer Wegovy injections and oral Wegovy, pending FDA approval, through its platform.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hims &amp; Hers Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251103753411) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Health Inc. reports Q3 revenue up 49% year over year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Health Inc. reports Q3 revenue up 49% year over year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 05:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hims &amp; Hers Health Inc. reports Q3 revenue up 49% year over year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hims &amp; Hers Health Inc. reported third quarter 2025 revenue growth of 49% year over year. Adjusted EBITDA increased by 53% year over year. Free cash flow for the third quarter was $79.4 million, unchanged from the same period in 2024. For the fourth quarter of 2025, the company expects revenue between $605 million and $625 million, and Adjusted EBITDA of $55 million to $65 million, with a projected Adjusted EBITDA margin of 9% to 10%. Full year 2025 revenue is expected to be between $2.3 billion and $2.4 billion. The company is in ongoing discussions with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> to potentially offer Wegovy injections and oral Wegovy, pending FDA approval, through its platform.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hims &amp; Hers Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251103753411) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL7r7l2J:1","article_id":"2580540228","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580540228","pubTimestamp":1762204031,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hims & Hers Health Inc. reported third quarter 2025 revenue growth of 49% year over year. Adjusted EBITDA increased by 53% year over year. Free cash flow for the third quarter was $79.4 million, unchanged from the same period in 2024. For the fourth quarter of 2025, the company expects revenue between $605 million and $625 million, and Adjusted EBITDA of $55 million to $65 million, with a projected Adjusted EBITDA margin of 9% to 10%. Full year 2025 revenue is expected to be between $2.3 billion and $2.4 billion. The company is in ongoing discussions with Novo Nordisk to potentially offer Wegovy injections and oral Wegovy, pending FDA approval, through its platform.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hims & Hers Health Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Hims&Hers Health Inc.报告第三季度收入同比增长49%","themeId":"6b43f5868e1a5ac8f736ff2144c2c120","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{},"content_text":"Hims & Hers Health Inc. reports Q3 revenue up 49% year over year\n    \n\n        Hims & Hers Health Inc. reported third quarter 2025 revenue growth of 49% year over year. Adjusted EBITDA increased by 53% year over year. Free cash flow for the third quarter was $79.4 million, unchanged from the same period in 2024. For the fourth quarter of 2025, the company expects revenue between $605 million and $625 million, and Adjusted EBITDA of $55 million to $65 million, with a projected Adjusted EBITDA margin of 9% to 10%. Full year 2025 revenue is expected to be between $2.3 billion and $2.4 billion. The company is in ongoing discussions with Novo Nordisk to potentially offer Wegovy injections and oral Wegovy, pending FDA approval, through its platform.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hims & Hers Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251103753411) on November 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}